FDA panel rejects GSK's Blenrep combo due to severe ocular toxicity and dosing concerns in multiple myeloma trials ahead of ...

London stocks had pared gains by midday on Friday, with GSK under the cosh. The FTSE 100 was flat at 8,971.33, having ...

An important point about the updated guidelines is the emphasis on individualized treatment of complicated UTIs, recognizing ...

The FTSE 100 index was up just 4.95 points at 8,977.59. The FTSE 250 gained 109.90 points, 0.5%, at 21,876.33, and the AIM All-Share climbed 2.54 points, 0.3%, at 771.47.

With the aim of being the largest life sector by 2035 behind only the US and China, the UK government is ramping up commercialisation.

Jaguar Land Rover announces job losses, Barclays cuts mortgage rates as low as 3.75% - Latest stock markets updates, business ...

Find insight on GSK, Novartis , Sarepta Therapeutics and more in the latest Market Talks covering Health Care.

The panel expressed concerns about the proposed doses of Blenrep (belantamab mafodotin) in GSK's marketing application, ...

Administering Shingrix previously required combining a lyophilised antigen with a liquid adjuvant from two separate vials.

GSK shares fell after a Food and Drug Administration advisory committee voted against approval of the company's Blenrep drug, a setback for its bid to reintroduce the blood-cancer treatment in the U.S ...

FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the ...